Cargando…
Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan
INTRODUCTION: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. METHODS: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360604/ https://www.ncbi.nlm.nih.gov/pubmed/30766912 http://dx.doi.org/10.1016/j.trci.2018.06.013 |
_version_ | 1783392528170483712 |
---|---|
author | Chang, Chee-Jen Chou, Tse-Chih Chang, Chiung-Chih Chen, Ta-Fu Hu, Chaur-Jong Fuh, Jong-Ling Wang, Wenfu Chen, Chiung-Mei Hsu, Winco Huang, Chin-Chang |
author_facet | Chang, Chee-Jen Chou, Tse-Chih Chang, Chiung-Chih Chen, Ta-Fu Hu, Chaur-Jong Fuh, Jong-Ling Wang, Wenfu Chen, Chiung-Mei Hsu, Winco Huang, Chin-Chang |
author_sort | Chang, Chee-Jen |
collection | PubMed |
description | INTRODUCTION: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. METHODS: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. RESULTS: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. DISCUSSION: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined. |
format | Online Article Text |
id | pubmed-6360604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63606042019-02-14 Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan Chang, Chee-Jen Chou, Tse-Chih Chang, Chiung-Chih Chen, Ta-Fu Hu, Chaur-Jong Fuh, Jong-Ling Wang, Wenfu Chen, Chiung-Mei Hsu, Winco Huang, Chin-Chang Alzheimers Dement (N Y) Featured Article INTRODUCTION: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. METHODS: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. RESULTS: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. DISCUSSION: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined. Elsevier 2018-07-17 /pmc/articles/PMC6360604/ /pubmed/30766912 http://dx.doi.org/10.1016/j.trci.2018.06.013 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Featured Article Chang, Chee-Jen Chou, Tse-Chih Chang, Chiung-Chih Chen, Ta-Fu Hu, Chaur-Jong Fuh, Jong-Ling Wang, Wenfu Chen, Chiung-Mei Hsu, Winco Huang, Chin-Chang Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title_full | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title_fullStr | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title_full_unstemmed | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title_short | Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan |
title_sort | persistence and adherence to rivastigmine in patients with dementia: results from a noninterventional, retrospective study using the national health insurance research database of taiwan |
topic | Featured Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360604/ https://www.ncbi.nlm.nih.gov/pubmed/30766912 http://dx.doi.org/10.1016/j.trci.2018.06.013 |
work_keys_str_mv | AT changcheejen persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT choutsechih persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT changchiungchih persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT chentafu persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT huchaurjong persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT fuhjongling persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT wangwenfu persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT chenchiungmei persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT hsuwinco persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan AT huangchinchang persistenceandadherencetorivastigmineinpatientswithdementiaresultsfromanoninterventionalretrospectivestudyusingthenationalhealthinsuranceresearchdatabaseoftaiwan |